我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

胺碘酮转复持续性房颤的临床经验——附70例疗效分析(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
1996年第3期
页码:
149-152,156
栏目:
论著
出版日期:
1996-05-01

文章信息/Info

Title:
Clinical experience of oral Am iodarone in converting persistent atrial fibrillation——Analysis of 70 cases
作者:
毕爱华　胡际和
上海嘉定区中心医院内科　上海 201800
Author(s):
Bi Aihua;  Hu Jihe
Medicine Department of Jiading District Central Hospital, Shanghai 201800
关键词:
胺碘酮;  心房纤颤;  心室功能
Keywords:
Amiodarone;  atrial fibrillation;  ventricular function
分类号:
-
DOI:
-
文献标识码:
-
摘要:
本文总结口服胺碘酮转复持续性房颤70例的疗效, 分析影响疗效的因素和毒副反应。结果: 总有效率为74.3% (52/70)。患者年龄、基础心脏病、左房内径大小对复律成功与否无影响。有影响的因素为房颤持续时间和心功能状态。用药后房颤的f波幅升高, 频率减慢, 提示心功能改善, 可预告复律将成功。胺碘酮的毒副反应轻, 发生率低。但长期应用要警惕潜在的肺、肝和神经系统的严重毒性作用。
Abstract:
This paper reports the efficacy and adverse reaction of oral Amiodarone in the treatment of 70 patients with persistent atrial fibrillation (Af). The results showed that the total success rate was 74.3% (52/70). The left atrial size, age and underlying heart disease were not helpful in predicting the result at Amiodarone therapy. The duration of Af and cardiac functional condition appeared to be an adverse factor. During the therapy, an increase in the amplitude and a decrease in the frequency of the f wave in the Af predicted convertion to normal sinus rhythm , it shows that the heart functions will become well . Adverse reactions in most cases were mild and tolerable. However, in the long-term application the occurrence of potential serious side effects needs attention particularly in the lung, liver and neural system.

参考文献/References

［1］胡际和, 陈灏珠. 胺碘酮抗心律失常临床应用的评价. 国外医学内科学分册1992; 19 (2) : 66.

［2］Wilson IS, Padrid PJ. Side effects from Amiodaron. Am Heart J 1991; 121 ( I part 2) : 158.

［3］Sanfilipp AJ , Abascal VM , Mary S, et al. Atrial.enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study.Circulation 1990; 82 (3) : 792.

［4］胡际和, 陈灏珠. 胺碘酮抗心律失常机制和药理学作用研究的进展. 临床心血管病杂志1992; 8(增刊) : 104.

［5］Goldman DS. Antiarrhythmic Therapy for atrial fibrillation: Current status. Primary Cardiol1994; 20 (11) : 15.

［6］Ceremuzynski L. Secondary prevention after myocardial infarction: Class Ⅲ antiarrhythmic drugs. Am J Cardiol 1993; 72 (16) : 82F.

［7］胡婉英, 杨舜华, 吕宝经. 血钾过高致心房颤动转变为窦性心律1 例. 上海医学1984; 7 (10) :599.

［8］Jorens PG, Henvel DH, Parizel GA , et al. 　Amiodaron and Tasadesde Ponint. Am Heart J 1991; 120 (6) : 1482.

[9]张聚静. 大剂量胺碘酮转复房颤40 例. 临床荟萃1995; 10 (2) : 79.

备注/Memo

备注/Memo:
Received 1995-210-10
更新日期/Last Update: 1996-05-01